Last-Resort drug opens for rare cancer patients
NCT ID NCT07502716
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This program provides early access to ubamatamab for people with two rare and aggressive cancers: renal medullary carcinoma and epithelioid sarcoma. The drug is given on a case-by-case basis to those who have no other treatment options. The goal is to offer a potential treatment when standard therapies are exhausted.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EPITHELIOID SARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug shrink Hard-to-Treat childhood cancers?
- Experimental drug opens door for rare sarcoma patients with no options left
- New experimental pill takes on tough cancers
- Researchers watch and learn: no new treatment for rare sarcoma
- Scientists launch deep dive into rare sarcomas to unlock immune secrets
- New hope for rare childhood cancer: drug cocktail aims to shrink tumors and prevent return